Literature DB >> 3351378

Gaucher-like changes in human blood-derived macrophages induced by beta-glucocerebrosidase inhibition.

S Yatziv1, D S Newburg, N Livni, G Barfi, E H Kolodny.   

Abstract

Human blood-derived macrophages were cultured in the presence of conduritol-B-epoxide, a specific inhibitor of beta-glucosidase, to induce changes resembling those occurring in the cells of patients with Gaucher's disease. After 24 hours of incubation, only 5% of the original beta-glucosidase activity remained; on removal of the inhibitor, the enzyme activity recovered almost fully to control levels after 5 days. After 30 days of incubation with conduritol-B-epoxide, the macrophages contained almost 10 times as much glucocerebroside as the untreated controls, and the cells displayed morphologic changes reminiscent of Gaucher's cells. This in vitro system may enable detailed studies on the pathogenetic mechanisms associated with glucocerebroside accumulation in human macrophages as well as on the turnover of the accumulated substrate and reversal of the morphologic abnormalities on removal of the inhibitor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3351378

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  3 in total

1.  Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.

Authors:  U H Schueler; T Kolter; C R Kaneski; G C Zirzow; K Sandhoff; R O Brady
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

2.  Screening and optimization of ligand conjugates for lysosomal targeting.

Authors:  Igor Meerovich; Alexander Koshkaryev; Ritesh Thekkedath; Vladimir P Torchilin
Journal:  Bioconjug Chem       Date:  2011-10-06       Impact factor: 4.774

3.  Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro.

Authors:  Ritesh Thekkedath; Alexander Koshkaryev; Vladimir P Torchilin
Journal:  Nanomedicine (Lond)       Date:  2012-12-02       Impact factor: 5.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.